Normandy Center for Genomic and Personalized Medicine

Sotteville-lès-Rouen, France

Normandy Center for Genomic and Personalized Medicine

Sotteville-lès-Rouen, France
SEARCH FILTERS
Time filter
Source Type

Fontanilles M.,Cancer Center Henri Becquerel | Fontanilles M.,French Institute of Health and Medical Research | Marguet F.,Neovasc | Marguet F.,Normandy Center for Genomic and Personalized Medicine | And 19 more authors.
Oncotarget | Year: 2017

Purpose: Primary central nervous system lymphomas (PCNSL) have recurrent genomic alterations. The main objective of our study was to demonstrate that targeted sequencing of circulating cell-free DNA (cfDNA) released by PCNSL at the time of diagnosis could identify somatic mutations by next-generation sequencing (NGS). Patients and Methods: PlasmacfDNA and matched tumor DNA (tDNA) from 25 PCNSL patients were sequenced using an Ion Torrent Personal Genome Machine (Life Technologies®). First, patient-specific targeted sequencing of identified somatic mutations in tDNA was performed. Then, a second sequencing targeting MYD88 c.T778C was performed and compared to plasma samples from 25 age-matched control patients suffering from other types of cancer. Results: According to the patient-specific targeted sequencing, eight patients (32% [95% CI 15-54%]) had detectable somatic mutations in cfDNA. Considering MYD88 sequencing, six patients had the specific c.T778C alteration detected in plasma. Using a control group, the sensitivity was 24% [9-45%] and the specificity was 100%. Tumor volume or deep brain structure involvement did not influence the detection of somatic mutations in plasma. Conclusion: This pilot study provided evidence that somatic mutations can be detected by NGS in the cfDNA of a subset of patients suffering from PCNSL. © Fontanilles et al.

Loading Normandy Center for Genomic and Personalized Medicine collaborators
Loading Normandy Center for Genomic and Personalized Medicine collaborators